Five Prime Promotes Bryan Irving to Chief Scientific Officer

Xconomy San Francisco — 

Bryan Irving is now executive vice president and chief scientific officer of Five Prime Therapeutics (NASDAQ: FPRX). Irving first joined South San Francisco-based Five Prime last year as vice president of research. His experience also includes posts at CytomX Therapeutics (NASDAQ: CTMX) and Genentech. Clinical-stage Five Prime develops protein therapies to treat cancer and inflammatory diseases.